-Author name in bold denotes the presenting author
-Asterisk * with author name denotes a Non-ASH member
Clinically Relevant Abstract denotes an abstract that is clinically relevant.

PhD Trainee denotes that this is a recommended PHD Trainee Session.

Ticketed Session denotes that this is a ticketed session.

279 Simultaneous Targeting of CD19 and CD22: Phase I Study of AUTO3, a Bicistronic Chimeric Antigen Receptor (CAR) T-Cell Therapy, in Pediatric Patients with Relapsed/Refractory B-Cell Acute Lymphoblastic Leukemia (r/r B-ALL): Amelia Study

Program: Oral and Poster Abstracts
Type: Oral
Session: 614. Acute Lymphoblastic Leukemia: Therapy, excluding Transplantation: Chimeric Antigen Receptor T-cell therapy in ALL: What Is Next?
Hematology Disease Topics & Pathways:
Biological, Therapies, CAR-Ts, gene therapy, immunotherapy
Sunday, December 2, 2018: 8:00 AM
Ballroom 20D (San Diego Convention Center)

Persis J Amrolia, FRCP, FRCPath, PhD1*, Robert Wynn, MD2, Rachael Hough, MD, BMBS, FRCP, FRCPath3*, Ajay Vora, MD4, Denise Bonney5*, Paul Veys, MD, PhD6*, Kanchan Rao7*, Robert Chiesa8*, Muhammad Al-Hajj9*, Shaun P Cordoba, PhD10*, Shimobi Onuoha, PhD10*, Ekaterini Kotsopoulou10*, Nushmia Z Khokhar10*, Martin Pule, PhD10* and Vijay G R Peddareddigari10*

1Bone Marrow Transplantation Department, Great Ormond Street Hospital, London, United Kingdom
2Dept. of Blood and Marrow Transplantation, Royal Manchester Children's Hospital, Manchester, United Kingdom
3Stem Cell Transplant, University College London Hospital, London, United Kingdom
4Department of Haematology, Great Ormond Street Hospital, London, United Kingdom
5Department of Blood and Marrow Transplant, Royal Manchester Children's Hospital, Manchester, United Kingdom
6Great Ormond Street Hospital, London, United Kingdom
7Bone Marrow Transplant, Great Ormond Street Hospital, London, United Kingdom
8Bone Marrow Transplantation Department, Great Ormond Street hospital NHS Trust, London, ENG, United Kingdom
9Autolus Ltd, London, GBR
10Autolus Ltd, London, United Kingdom

Introduction CAR T-cell therapies directed against CD19 or CD22 antigens have shown significant activity in pediatric patients with r/r B-ALL. Whilst complete response (CR) rates of 70‒90% have been observed, relapse due to target antigen downregulation or loss is the major cause of treatment failure. This Phase I/II study evaluates the safety and efficacy of AUTO3, a CAR T-cell therapy designed to target CD19 and CD22 simultaneously in order to reduce the likelihood of relapse due to antigen loss.

Methods & Patients

We constructed a novel bicistronic retroviral vector encoding both an anti-CD19 CAR and an anti-CD22 CAR. Antigen binding domains were humanized and both CARs are in “2nd generation” format (incorporating an OX40 co-stimulatory domain for the CD19 CAR and a 41BB for the CD22 CAR). The performance of the CD22 CAR was optimized by incorporating a novel pentameric spacer. The cell product was manufactured on a semi-automated and closed process using CliniMACS® Prodigy (Miltenyi Biotec).

Patients (1‒24 years of age) with high risk relapse (IBFM criteria) or relapse post-allogeneic stem cell transplant (SCT), adequate performance score/organ function, and an absolute lymphocyte count ≥0.5 x 109/L are eligible. Patients with CNS 3 disease, active graft versus host disease, and clinically significant infection or serious toxicity from prior CAR T-cell are excluded.

Patients receive lymphodepletion with 30 mg/m2/day fludarabine x 4 days and 500 mg/m2/day cyclophosphamide x 2 days prior to AUTO3 infusion. Three dose levels are being explored (1 x 106, 3 x 106, and 5 x 106 transduced CAR+ T cells/kg) and CAR T cells are infused as a single (for <25% blasts) or split (for >25% blasts) dose based on leukemia burden. Bridging therapy is allowed during the manufacturing period. The primary endpoint of Phase I is the frequency of dose-limiting toxicities (DLTs) and key secondary endpoints include proportion of patients achieving a morphological/minimal residual disease (MRD) negative CR, disease-free survival, overall survival, as well as biomarker endpoints including AUTO3 levels and persistence in blood and bone marrow.

Results

As of the data cut-off date (July 16, 2018), 9 patients have been enrolled and 8 have received AUTO3. It was possible to generate a product in all patients and the median transduction efficiency was 16% (range 9‒34%). Median age was 7.5 years (range 4‒16 years) and 5 (63%) patients had prior SCT. One patient (13%) had prior anti-CD19 CAR-T cells and blinatumomab. The disease burden at Day ‒7 ranged from 0% to 90% leukemic blasts.

Eight patients had a minimum of 4 weeks’ follow up and were evaluable for safety and efficacy analysis. Three patients received ≤1 × 106 CAR T cells/kg as single dose, 1 patient received 2 × 106/kg as split dose, and 4 received 3 × 106 CAR cells/kg (3 single infusions, 1 split). No AUTO3 related deaths and no DLTs were observed. The most common grade (Gr) ≥3 adverse events were neutropenia (63%), febrile neutropenia (50%), pyrexia (25%), and anemia (25%). Five patients (63%) had Gr 1 cytokine release syndrome (CRS); no Gr 2 or higher CRS was seen. Five patients (63%) experienced neurotoxicity: 4 had Gr 1 and 1 patient (13%) had Gr 3 encephalopathy that was considered likely related to prior intrathecal methotrexate. No patients required ICU admission.

Six of 8 patients achieved MRD negative CR, giving an objective response rate of 75% (95% CI 34.9‒96.8%) at 1 month. In patients treated at doses <3 x 106/kg, 3 responded but subsequently relapsed. Importantly, no loss of CD19 or CD22 was noted in patients that relapsed. All 4 patients treated at the higher dose of 3 × 106 CAR T cells/kg had an MRD negative CR with ongoing remission and B-cell aplasia, with the longest follow up of 4 months. CAR T-cell expansion was enhanced in patients receiving 3 x 106/kg (median 79,282
copies/µg DNA in blood at peak) compared to those receiving lower doses (median 10,243 copies/µg DNA).

Conclusion

This interim data analysis demonstrates for the first time the feasibility and safety of simultaneous targeting of CD19 and CD22 with AUTO3. Promising efficacy was demonstrated at a dose level of 3 × 106 CAR T cells/kg, as 4/4 patients achieved MRD complete remission with no antigen negative escape at this early stage. The study continues to enrol and updated follow up and additional patient data at higher dose levels, as well as cellular kinetics and additional biomarker analysis, will be presented.

Disclosures: Amrolia: Autolus PLC: Patents & Royalties; Bluebird Bio: Research Funding. Wynn: Orchard SAB: Membership on an entity's Board of Directors or advisory committees; Orchard Therapeutics: Equity Ownership; Chimerix: Research Funding; Genzyme: Honoraria; Bluebird Bio: Consultancy; Orchard Therapeutics: Consultancy; Chimerix: Consultancy. Hough: University College London Hospital’s NHS Foundation Trust: Employment. Vora: Amgen: Other: Advisory board; Medac: Other: Advisory board; Novartis: Other: Advisory board; Pfizer: Other: Advisory board; Jazz: Other: Advisory board. Veys: Servier: Research Funding; Pfizer: Honoraria; Novartis: Honoraria. Chiesa: Gilead: Consultancy; Bluebird Bio: Consultancy. Al-Hajj: Autolus Ltd: Employment; Autolus Ltd: Equity Ownership. Cordoba: Autolus Ltd: Employment; Autolus Ltd: Equity Ownership; Autolus Ltd: Patents & Royalties. Onuoha: Autolus Ltd: Employment, Equity Ownership, Patents & Royalties. Kotsopoulou: Autolus Ltd: Equity Ownership; Autolus Ltd: Employment. Khokhar: Autolus Ltd: Employment; Autolus Ltd: Equity Ownership. Pule: Autolus Ltd: Employment, Equity Ownership, Other: Salary contribution paid for by Autolus, Research Funding; University College London: Patents & Royalties: Patent with rights to Royalty share through UCL. Peddareddigari: Autolus Therapeutics plc: Equity Ownership; Autolus Therapeutics plc: Patents & Royalties; Autolus Therapeutics plc: Employment.

*signifies non-member of ASH